Back to mobile site

MannKind (MNKD) Posts Q3 Loss of 9c/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. SPY
7. TSLA
8. DPZ
9. NVDA
10. PRIM

November 3, 2014 9:02 AM EST

MannKind (NASDAQ: MNKD) reported Q3 EPS of ($0.09), $0.13 worse than the analyst estimate of $0.04.

Cash and cash equivalents were $172.5 million at September 30, 2014, compared to $41.2 million in the second quarter of 2014. In the third quarter of 2014, the Company received:

  • $150.0 million in an upfront payment from Sanofi in connection with the closing of the collaboration and licensing agreement;
  • $40.0 million from the Tranche 4 notes purchased by Deerfield in July 2014; and
  • $17.3 million in proceeds from warrant and stock option exercises.

Cash and cash equivalents were $172.5 million at September 30, 2014, compared to $41.2 million in the second quarter of 2014. In the third quarter of 2014, the Company received:

  • $150.0 million in an upfront payment from Sanofi in connection with the closing of the collaboration and licensing agreement;
  • $40.0 million from the Tranche 4 notes purchased by Deerfield in July 2014; and
  • $17.3 million in proceeds from warrant and stock option exercises.
- See more at: http://globenewswire.com/news-release/2014/11/03/679110/10105866/en/MannKind-Corporation-Reports-2014-Third-Quarter-Financial-Results.html#sthash.6YkdK1Ot.dpuf

Cash and cash equivalents were $172.5 million at September 30, 2014, compared to $41.2 million in the second quarter of 2014. In the third quarter of 2014, the Company received:

  • $150.0 million in an upfront payment from Sanofi in connection with the closing of the collaboration and licensing agreement;
  • $40.0 million from the Tranche 4 notes purchased by Deerfield in July 2014; and
  • $17.3 million in proceeds from warrant and stock option exercises.
- See more at: http://globenewswire.com/news-release/2014/11/03/679110/10105866/en/MannKind-Corporation-Reports-2014-Third-Quarter-Financial-Results.html#sthash.6YkdK1Ot.dpuf

Cash and cash equivalents were $172.5 million at September 30, 2014, compared to $41.2 million in the second quarter of 2014. In the third quarter of 2014, the Company received:

  • $150.0 million in an upfront payment from Sanofi in connection with the closing of the collaboration and licensing agreement;
  • $40.0 million from the Tranche 4 notes purchased by Deerfield in July 2014; and
  • $17.3 million in proceeds from warrant and stock option exercises.
- See more at: http://globenewswire.com/news-release/2014/11/03/679110/10105866/en/MannKind-Corporation-Reports-2014-Third-Quarter-Financial-Results.html#sthash.6YkdK1Ot.dpuf

For earnings history and earnings-related data on MannKind (MNKD) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings